A5024318722- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Helicobacter pylori-related gastroenterology studies
- Gastroesophageal reflux and treatments
- Liver Disease and Transplantation
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Pediatric Hepatobiliary Diseases and Treatments
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Veterinary medicine and infectious diseases
- Eosinophilic Esophagitis
- Cancer Mechanisms and Therapy
- Ocular Infections and Treatments
- Colorectal Cancer Screening and Detection
- Intraocular Surgery and Lenses
- Gastrointestinal disorders and treatments
- Multiple and Secondary Primary Cancers
- Clostridium difficile and Clostridium perfringens research
- Esophageal and GI Pathology
- Gastrointestinal Bleeding Diagnosis and Treatment
Kaohsiung Chang Gung Memorial Hospital
2016-2025
Chang Gung University
2015-2024
Chiayi Chang Gung Memorial Hospital
2012-2018
National Yang Ming Chiao Tung University
2016
Kaohsiung Medical University Chung-Ho Memorial Hospital
2015
Kaohsiung Medical University
2015
Chang Gung Memorial Hospital
2001-2009
Royal Adelaide Hospital
2008
Memorial Hospital of South Bend
2001-2007
The first-line eradication rate of standard triple therapy for Helicobacter pylori infection has declined to <80%, and alternative therapies with >90% success rates are needed. Inconsistent were reported proton pump inhibitor- amoxicillin-containing high-dose dual therapy. We performed a prospective, randomized controlled study assess the efficacy esomeprazole- investigated influencing clinical factors. recruited 240/278 eligible H. pylori-infected patients after exclusion. They randomly...
OBJECTIVES: To compare the efficacy of hepatocellular carcinoma (HCC) surveillance at 4- and 12-month intervals in a community for patients with chronic viral hepatitis thrombocytopenia. METHODS: In 10 townships, adults (≥40 years) platelet ≤150 (×109)/l, positive B surface antigen, or antibody to C virus were invited this study. These townships randomized into (group A) B) interval groups. Seven hundred eighty-five 796 residents met study criteria groups A B. Ultrasonography (US) was...
Abstract Background and Aim The Albumin‐Bilirubin (ALBI) grade is a new index to assess objectively liver function prognosis in patients with hepatocellular carcinoma (HCC). This study aimed elucidate the application of ALBI baseline sorafenib‐end advanced HCC who received sorafenib. Methods A total 415 consecutive Child–Pugh sorafenib our hospital. Sorafenib was terminated when radiologic tumor progression or clinical deterioration (LD) occurred reassessment bimonthly. Patients failed...
Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma (uHCC). This study was designed to assess clinical impact of atezolizumab in uHCC patients. A total 48 receiving were identified, including first-line, second-line, third-line, and later-line settings. In these patients, median progression-free survival (PFS) 5.0 months, months treatment, not reached second-line 2.5 third line later treatment. The...
Abstract Background Large meta‐analyses of second‐line H elicobacter pylori eradication with fluoroquinolone triple therapy have shown that neither 7‐day nor 10‐day provides 90% or better treatment success. Reports describing . using 14‐day fluoroquinolone‐containing are few. Current study aimed to determine the efficacy a levofloxacin/amoxicillin/proton‐pump inhibitor regimen as and clinical factors influencing outcome. Materials methods One‐hundred one patients who failed standard for 7...
Foreign object ingestion and food bolus impaction are a common clinical problem. We report our experiences in endoscopic management for adults, foreign body ingestion, impaction.A retrospective chart review study was conducted on adult patients with between January 2011 November 2014. Patients incomplete medical records were excluded.A total of 198 (226 incidents) included the (male/female: 1.54/1; age 57 ± 16 years). Among them, 168 bodies found successfully (74.3%). 75.6% located...
ABSTRACT A new hepatitis C virus (HCV) core antigen (HCV Ag) assay was thought to have a good correlation with HCV RNA. The aim elucidate the usefulness of this Ag in community screening. In township where is endemic, 405 residents aged 58 years or older responded follow-up All subjects were tested for anti-HCV (AxSYM, version 3.0; Abbott Diagnostics) and (Architect test; Diagnostics). For signal-to-cutoff ratios (S/CO) > 10 and/or 3 fmol/liter, RNA data (Taqman RNA; Roche further...
Our objective was to develop a predictive nomogram that could estimate the long-term survival of patients with very early/early-stage hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA). For this retrospective study, we enrolled 950 who initially received curative RFA for HCC at Barcelona Clinic Liver Cancer (BCLC) stages 0 and A between 2002 2016. Factors predicting poor after were investigated through Cox proportional hazard model. The constructed using variables...
Nivolumab and pembrolizumab have not been directly compared in clinical trials, the aim of this study is to investigate efficacy safety nivolumab versus patients with advanced hepatocellular carcinoma (HCC) real-world practice.We retrospectively reviewed HCC who received intravenous or alone as second-line later therapy. The objective response was determined according Response Evaluation Criteria Solid Tumors criteria version 1.1. Adverse events (AEs) were graded based on National Cancer...
Atezolizumab plus bevacizumab (Ate/Bev) and lenvatinib (Len) are first-line therapies for unresectable hepatocellular carcinoma (uHCC). However, Ate/Bev's high cost limits its common use in real-life practice, while Len is usually covered by national health insurance (NHI). We conducted this study to compare their effectiveness safety real-world settings. retrospectively evaluated 346 uHCC patients treated with Ate/Bev (n=80) or (n=266) from December 2019 2022, using 1:2 ratio propensity...
We aimed to investigate the natural course of hepatic focal nodular hyperplasia (FNH) in a long-term follow-up study with sonography.This comprised 30 patients (24 women and 6 men) 34 FNHs. Diagnosis FNH was made using color Doppler sonography, contrast-enhanced CT, or MRI combination needle biopsy. Patients were followed every 3 months sonography. Regression progression tumor defined as change over 30% maximal diameter. Disappearance no vizualization on at least sonographic...
Summary Background The impact of metabolic syndrome (MetS) on hepatitis is an interesting issue. Aim To evaluate the association MetS and chronic viral including B virus ( HBV ) C HCV infection in southern Taiwan. Methods From 2004 to 2013, a series community‐based health screenings for residents aged 40 older were held Tainan city. was defined according Joint Scientific Statement. Cut‐offs body‐mass index measures 24 kg/m 2 27 used stratify lean, overweight obese subjects. Results We...
Lenvatinib is approved for patients with advanced hepatocellular carcinoma (HCC) due to its non-inferiority sorafenib of overall survival (OR) in clinical trials. This study was compare the effectiveness and safety lenvatinib real world.We retrospectively evaluated 338 unresectable HCC who had undergone or treatment between January 2018 August 2020. Propensity-score matching analysis performed a 1:2 ratio reduce real-life baseline difference two groups.A total 210 (Male/Female: 150/60, mean...
This study was conducted to determine whether the causes of death among patients with hepatocellular carcinoma (HCC) differ according chronic liver disease (CLD) etiology. Between 2011 and 2020, 3977 who were newly diagnosed HCC at our institution enrolled in this study. We determined cause HCC-related non-HCC-related. For multiple CLD etiologies, etiology classified using following hierarchy: hepatitis C virus (HCV) > B (HBV) alcohol-related all negative. All negative defined as for HCV,...
Liver stiffness measurement (LSM) using transient elastography has been proposed to assess liver fibrosis well in various diseases. This study was determine the changes of LSM and its associated factors for chronic hepatitis B (CHB) patients undergoing Entecavir therapy. Consecutive CHB underwent therapy with two LSMs were enrolled. Patients aspartate transaminase (AST) and/or alanine ≧200 IU/L excluded. The retrospective enrolled 233 including 132 without cirrhosis (group 1) 101 2). mean...
ABSTRACT Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are effective antivirals recommended as first-line monotherapies for treatment of chronic hepatitis B (CHB) infection. This study aimed to compare the short-term efficacies TDF ETV in CHB with severe acute exacerbation. From 2008 2013, 189 consecutive treatment-naive patients receiving ( n = 41) or 148) exacerbation were enrolled. The primary endpoint was overall mortality receipt liver transplantation by week 24. baseline...
Whether some diseases are related to the occurrence of synchronous colorectal carcinoma (sCRC) is unknown. Investigating risk factors and presentation sCRC could aid in treatment patients with cancer (CRC). The prognosis compared that solitary CRC remains unclear.A total 17 093 were recruited between 1st January 1995 31th December 2016. development assessed using univariate multivariate logistic regression. effect on survival was analysed Cox regression model.The prevalence 5.6% this study....
This prospective study was to assess the efficacy of nonbismuth containing quadruple therapy as first-line H. pylori treatment and determine clinical factors influencing patient outcome. We enrolled 200 -infected naïve patients. They were prescribed either a 7-day group (EACM, esomeprazole 40 mg twice daily, amoxicillin 1 g metronidazole 500 clarithromycin daily) or standard triple (EAC, daily). Follow-up studies responses carried out 8 weeks later. The eradication rates attained by EACM EAC...
Nivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure. This study compared the effectiveness of nivolumab following sorafenib.We retrospectively enrolled HCC who had undergone or Treatment response, treatment-related adverse events (TRAE) clinical outcomes were recorded analyzed.A total 90 (male/female: 67/23, mean age: 63 years) enrolled, including 32 in group 58 Regorafenib group. The better objective response...